Cancer Research Institute
Clinical Trials
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
This study looks at how well a drug called selumetinib works when given to children and young adults with LGG. The study doctors want to see if selumetinib works as well as CV for getting rid of or shrinking LGGs and stopping t ...
A Phase 3 Randomized Study of Selumetinib (IND# 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
The overall goals of this study are to see if selumetinib works just as well as the standard treatment of carboplatin/vincristine (CV) for subjects with NF1-associated LGG, and to see if selumetinib is better than CV in improvi ...
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
The overall goal of this study is to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better. This study will compare standard chemotherap ...
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Low Risk Subjects (Age <50 Years): The overall goal is to see if monitoring subjects with low risk germ cell tumors after their tumor is removed is as effective as following surgery with chemotherapy and/or more surgery. Sta ...
A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
This study is being done to see how safe and effective four doses of the experimental drug oregovomab is when given through a vein in your arm at the same time as specific cycles of the chemotherapy regimen paclitaxel and carbo ...
A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDl3280A (Anti−PD-L1 Antibody) In Combination with Carboplatin and Nab-Paclitaxel for Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non−Small Cell Lung Cancer
[Abbreviated - Closed] The purpose of this study is to look at the effects, good or bad, of MPDL3280A on you and the specific type of lung cancer (non−small cell lung cancer [NSCLC]) from which you are suffering. MPDL3280A is a ...
A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-Derived Stem Cells (eASC), for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease Over a Period of 24 Weeks and a Follow-Up Period Up to 52 Weeks. ADMIRE-CD II Study.
The purpose of this study is to confirm (1) how well the study drug works at a single dose of 120 million cells compared to a placebo; (2) how safe and tolerable the study drug is in patients with fistulizing CD.
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
The purpose of this optional study is to test for biomarkers that help to understand the relationship between the study drug and your tumor.
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Subjects in Part 1 (Dose Finding Phase) Only: The overall goals of this study are: (1) to compare the effects, good and/or bad, of a new combination of chemotherapy using VAC/VI plus temsirolimus; (2) to find if adding the drug ...